Literature DB >> 3519229

Captopril in severe childhood hypertension--reversible anaemia with high dosage.

H A Verhaaren, J Vande Walle, A Devloo-Blancquaert.   

Abstract

Experience with chronic inhibition of the angiotensin-converting enzyme in children is limited to cases refractory to all other forms of treatment. In reports dealing with the use of captopril (Capoten-R) in children no important side-effects are mentioned. This report describes a 7-year-old boy with severe hypertension secondary to haemolytic uraemic syndrome. Good pressure control was obtained after introduction of captopril. However, under the high initial dosage, pronounced anaemia developed within the first 3 months of treatment. The anaemia responded to dose-reduction while pressure control was maintained. Serial echocardiographic studies were performed. They illustrate the beneficial haemodynamic effects of captopril in the follow-up of children under antihypertensive treatment. Some recommendations are made on the use of captopril in children.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3519229     DOI: 10.1007/bf00496034

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  26 in total

1.  Use of the oral angiotensin I--converting enzyme inhibitor (captopril) in childhood malignant hypertension.

Authors:  S E Oberfield; D B Case; L S Levine; R Rapaport; W Rauh; M I New
Journal:  J Pediatr       Date:  1979-10       Impact factor: 4.406

2.  Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney.

Authors:  D E Hricik; P J Browning; R Kopelman; W E Goorno; N E Madias; V J Dzau
Journal:  N Engl J Med       Date:  1983-02-17       Impact factor: 91.245

3.  Maintenance of the antihypertensive efficacy of captopril despite consistent reduction in daily dosage.

Authors:  A Mimran; B Jover
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

4.  Fatal pancytopenia associated with the use of captopril.

Authors:  I Gavras; L G Graff; B D Rose; J M McKenna; H R Brunner; H Gavras
Journal:  Ann Intern Med       Date:  1981-01       Impact factor: 25.391

Review 5.  Medical intelligence drug therapy: captopril.

Authors:  D G Vidt; E L Bravo; F M Fouad
Journal:  N Engl J Med       Date:  1982-01-28       Impact factor: 91.245

6.  [Successful treatment of renal hypertension in a 2 1/2-year-old girl with the converting enzyme inhibitor captopril (author's transl)].

Authors:  C Lütkenhaus; K Bonzel; L Diekmann; H Koch
Journal:  Monatsschr Kinderheilkd       Date:  1980-11       Impact factor: 0.323

Review 7.  Importance of adaptive changes in vascular design for establishment of primary hypertension, studied in man and in spontaneously hypertensive rats.

Authors:  B Folkow; M Hallbäck; Y Lundgren; R Sivertsson; L Weiss
Journal:  Circ Res       Date:  1973-05-05       Impact factor: 17.367

8.  Captopril. Long-term treatment of hypertension in a preterm infant and in older children.

Authors:  L C Hymes; B L Warshaw
Journal:  Am J Dis Child       Date:  1983-03

9.  Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone.

Authors:  G J Wenting; A J Man in't veld; A J Woittiez; F Boomsma; K Laird-Meeter; M L Simoons; P G Hugenholtz; M A Schalekamp
Journal:  Br Heart J       Date:  1983-01

10.  Factors related to first dose hypotensive effect of captopril: prediction and treatment.

Authors:  G P Hodsman; C G Isles; G D Murray; T P Usherwood; D J Webb; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-12
View more
  1 in total

1.  Erythropoiesis and Blood Pressure Are Regulated via AT1 Receptor by Distinctive Pathways.

Authors:  Hideki Kato; Junji Ishida; Taiji Matsusaka; Tomohiro Ishimaru; Keiji Tanimoto; Fumihiro Sugiyama; Ken-Ichi Yagami; Masaomi Nangaku; Akiyoshi Fukamizu
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.